I just found out. Is it too late?

It is not. APOE4 raises lifetime Alzheimer's risk roughly 4–5× above baseline, but it does not seal fate. The members with the largest biomarker swings are the ones who started in their fifties and sixties, every year of intervention bends the curve.

I am joining for a parent, partner, or someone I love.

You belong here too. Most of us started exactly where you are — 88% of members have a family history of Alzheimer's, and for nearly half it was their mother. Caregivers and family members get the same tools, pod, and expert access as every member, alongside people who have walked exactly your road.

I am not a biohacker.

Neither are most members, average member is a 58-year-old woman. The app walks you through every step, your pod keeps you honest, and Dr. Tran is one message away.

I am 3/4, not 4/4. Does this apply?

Yes. Phoenix is built for any APOE4 carrier. The urgency dial is lower, the playbook is the same.

Yes, any time, one click, no questions. 60-day full money-back guarantee on your first quarter.

Trials in Kentucky.

15 APOE4-relevant Alzheimer’s trials run in Kentucky — 2 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.

Where

Lexington · Louisville · Cynthiana · Danville · Midway · Versailles · Wilmore

Recruiting

2 of 15

Carriers enrolled, but higher ARIA riskNCT01767311
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
Built exclusively for APOE 4/4 carriersNCT02565511
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
Built specifically for APOE4 carriersNCT03131453
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
APOE4 carriers explicitly welcomedNCT04468659
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
Amyloid-focused, drug did not succeedNCT02008357
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
Open to carriers, not 4-specificNCT02814526
Exercise in Adults With Mild Memory Problems
This trial tests whether aerobic exercise (like treadmill walking) does more for brain health than stretching and balance routines in older adults with mild…
Observational only, no treatment involvedNCT02951598
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
Not APOE4-related, movement disorder focusNCT03924414
Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
Non-Alzheimer's focus, carriers may not qualifyNCT04120766
Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
This Phase 2 trial is testing nicorandil, a drug already used for heart conditions, to see whether it is safe and whether it affects a brain pathway linked to…
Not relevant to APOE4 carriersNCT04165109
Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
Open to carriers, not 4-specificNCT04262206
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
Late-stage dementia care, genotype not relevantNCT05644262
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
This Phase 2 trial is testing whether a liquid oral combination of THC and CBD (the two main active compounds in cannabis) can reduce agitation in people with…
Open to carriers, not 4-specificNCT06223360
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
This trial is testing benfotiamine — a fat-soluble form of vitamin B1 — at two different doses against a placebo, in people who already have early Alzheimer's…
Unrelated to APOE4 or dementiaNCT06516965
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
This Phase 3 trial is testing povorcitinib, a JAK inhibitor pill, against a placebo in people with prurigo nodularis — a chronic skin condition causing intense…
Late-stage dementia only, not carrier-focusedNCT06605157
A Multimodal Music Therapy Intervention for Engaging Persons With Severe Dementia
This pilot trial is testing whether a structured music therapy program called AMUSED, which includes live music, singing, and rhythm instruments, reduces…

Copy a forum-ready post

Keep exploring

An APOE4 carrier’s guide to clinical trials →Browse all hubs →

Educational, not medical advice. Trial decisions belong between you and your physician.